Rilpivirine-d6 (hydrochloride)
目录号 : GC48053
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Rilpivirine-d6 is intended for use as an internal standard for the quantification of rilpivirine by GC- or LC-MS. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51 nM.1 It is active against NNRTI-resistant HIV strains with EC50 values of less than 1 nM for L100I, K103N, V106A, G190A, and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = <10 nM), including strains containing up to eight resistance mutations. In vivo, rilpivirine, when used in combination with cabotegravir, lamivudine , and abcavir, reduces the plasma viral titer in HIV-1 infected humanized mice.2
1.Garvey, L., and Winston, A.Rilpivirine: A novel non-nucleoside reverse transcriptase inhibitorExpert Opin. Drug Discov.18(7)1035-1041(2009) 2.Arainga, M., Edagwa, B., Mosley, R.L., et al.A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapyRetrovirology14(1)17(2017)
| Cas No. | N/A | SDF | |
| Canonical SMILES | [2H]C([2H])([2H])C(C=C(/C=C/C#N)C=C1C([2H])([2H])[2H])=C1NC2=NC(NC3=CC=C(C#N)C=C3)=NC=C2.Cl | ||
| 分子式 | C22H12D6N6.HCl | 分子量 | 408.9 |
| 溶解度 | DMSO: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4456 mL | 12.2279 mL | 24.4559 mL |
| 5 mM | 0.4891 mL | 2.4456 mL | 4.8912 mL |
| 10 mM | 0.2446 mL | 1.2228 mL | 2.4456 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。